SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

SCYX

Scynexis
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor upcoming SCY-247 Phase 1 topline data in late 2026 and potential milestone payments from GSK on BREXAFEMME sales, which could provide additional non-dilutive funding and catalyze further value creation.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.34
T+0 close · Mar 4, 2026 · via day close
Latest settled
−15.93%
T+60 · $5.33
Vs SPY
−27.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $6.34entry
  2. T+1 · 9mo ago +0.95%α +2.26% · $6.40
  3. T+5 · 8mo ago +12.34%α +14.58% · $7.12
  4. T+20 · 8mo ago +12.04%α +15.83% · $7.10
  5. T+60 · 6mo ago −15.93%α −27.23% · $5.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Scynexis reported a significant year-over-year revenue increase to $20.6 million in 2025, driven by a $24.8 million one-time payment and catchup revenue from GSK, while R&D and SG&A expenses declined. The company ended the year with $56.3 million in cash, providing a runway of over two years, and advanced its SCY-247 program with Phase 1 IV dosing initiated and expanded access planned for 2026.

Key Financial Metrics

Revenue
$20.6M
+452.6% YoY
EPS
$-0.17
Deal Value
$24.8M

Key Facts

  • Revenue surged to $20.6 million in 2025 from $3.7 million in 2024, primarily due to $24.8 million in non-refundable payments and catchup revenue from GSK.
  • Net loss narrowed to $8.6 million from $21.3 million in 2024, with R&D expenses decreasing 15.6% year-over-year.
  • Cash, cash equivalents, and investments totaled $56.3 million as of December 31, 2025, providing a cash runway of more than two years.
  • SCY-247 IV formulation Phase 1 dosing initiated in February 2026, with topline data expected in second half of 2026; expanded access program planned for first half of 2026.
  • FDA granted QIDP and Fast Track designations for SCY-247 in January 2026.

Financial Impact

Revenue increased by $16.9 million YoY; cash position improved by $24.8 million from GSK payment despite operating outflows.

revenuecashnet lossoperating expenses

Risk Factors

  • Future revenue is heavily dependent on GSK's commercial success with BREXAFEMME and potential milestone payments.
  • SCY-247 development remains early-stage; clinical setbacks could impact valuation and funding strategy.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249748

Track record

14 reports on SCYX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
  2. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  4. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
  5. Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
  6. Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
  7. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
  8. Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
  9. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
  10. May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026